December 4th 2024
Many unvaccinated adults reported intent to get vaccinated, according to early season estimates released in MMWR.
October 30th 2024
Your daily dose of the clinical news you may have missed.
October 29th 2024
Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.
October 24th 2024
CDC Director Mandy Cohen endorsed the ACIP's recommendations, which also call for flexible dosing under shared clinical decision making.
The expanded recommendation includes shots from Merck (PCV21) and Pfizer (PCV20), and could be a "practice-changing milestone," one executive said.
Patient, Provider, and Caregiver Connection™: Prevention and Control of Meningococcal Disease — Individualizing Vaccine Recommendations in Adolescent Populations
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
Why Do We Need Another Pneumococcal Vaccine?
With 3 vaccines approved against pneumococcal disease in adults, is there really the need - or the room - for 1 more? Here's what one physician thinks.
The ACIP Recommends Use for a New Vaccine: Who Needs it?
The vaccine has been available in Europe for more than 20 years; the ACIP published recommendations in November. Will any of your patients need it?
Coadministration of RSV, Influenza Vaccines Found Safe and Effective in New Study
The coadministration of RSVpreF and seasonal influenza vaccine was found to generate robust immune responses in older adults, reported authors of new study.
When it Comes to the Monovalent COVID-19 Shot, the CDC and WHO Have a Disagreement
Should the monovalent COVID-19 vaccine approved for use this respiratory virus season be given universally or to only those at high risk? There are differences of opinion.
The Exam Room's Secret Weapon for Flu Season
Physician author Terry Brenneman, MD, suggests a key difference between a great clinician and an average one, and it has to do with used car sales. Read more.
Daily Dose: Arexvy May Protect Adults Aged 50-59 Years at Increased Risk for RSV
Immune Responses to Arexvy in Adults aged 50 to 59 Years Noninferior to those in Adults aged 60 Years and Older
The comparable immune responses were observed in 50-to 59-year-olds at high risk of RSV-LRTD as well as a wider group at average risk, according to preliminary phase 3 data.
Combination Influenza/COVID-19 Vaccine Enters Phase 3 Trial, First Participant Dosed
The investigational combination vaccine against influenza and SARS-CoV-2 proved both safe and effective in recent results from a phase 1/2 trial, said Moderna.
10 Top Studies from IDWeek for Primary Care, In Case you Missed Them
IDWeek was packed with so much new science it was hard to make choices. Here we topline 10 with outcomes of interest to primary care, ICYMI.
13 Reasons Patients Give for Not Getting a COVID-19 Vaccine Booster
Reasons for not getting a COVID-19 booster ranged from worry about taking time off to believing it won't add any additional protection from infection.
How to Get Shots into Arms this Year: Patience, Persistence, and Don't Take it Personally
AAFP president-elect Steven Furr, MD, offers 3 thoughts on maximizing opportunities this year to give all necessary vaccines.
AAFP President-Elect Steven Furr, MD, Talks About Vaccination in Practice vs in Theory
Furr on COVID-19 shot: The expectation that 90% of the US population would take this new vaccine that they'd never heard of was probably not practical.
Moderna Investigational Dual Flu/COVID-19 Vaccine Shows Positive Phase 1/2 Results
The combination was found equally as effective as 2 standard influenza vaccine comparators and as the Moderna Spikevax COVID-19 booster shot.
Nobel Prize Awarded to Scientists Whose Work on mRNA Led to Development of COVID-19 Vaccines
The pair of scientists was cited "for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19."
Moderna Investigational Influenza Vaccine Meets Safety, Efficacy Endpoints Across Phase 3 Trials
Moderna reported at its annual R&D day that its flu vaccine has met primary phase 3 endpoints and that phase 1/2 data show higher HIA titers vs Fluzone HD.
Keep the Vaccination Conversation Going—and Cheerlead, Too
"Keep the vaccination conversation going this year, even though your patients, and probably you, too, have grown tired of the issues and your team is worn out."
3 Dangerous Respiratory Viruses, 3 Robust Vaccines, 3 Shots at Broad Protection This Year
SARS-CoV-2, influenza, and respiratory syncytial virus are all targets this flu season for family physician Chuck Vega, MD, who says he's "going for all 3."
The Respiratory Syncytial Virus Vaccine for Older Adults: The New Shot on the Block
RSV is comparable to influenza every year in the severity of infection among older adults. Drs Bill Schaffner and Chuck Vega say both patients and clinicians will need education this season.
Expert Panel Offers Guidance on Testing for COVID-19, Influenza, RSV During Respiratory Virus Season 2023-2024
As flu season approaches this year, experts stress that it's not just about influenza anymore; they discuss testing, antiviral treatment, and management of coinfection.
The State of Vaccine Willingness in the US: A Primary Care and an Infectious Disease Physician Discuss
Well-known ID specialist Bill Schaffner, MD, and active primary care educator Chuck Vega, MD, offer thoughts on how to get shots into arms in the 2023-2024 respiratory virus season.
Respiratory Virus Season 2023-2024 is Shaping Up to be a Transitional One: Expert Interview
Respiratory virus season 2023-2024 will likely be a "transition year," according to family physician Chuck Vega, MD and ID specialist Bill Schaffner, MD. Here's why.
With New COVID-19 Variant on the Rise, Vaccine Manufacturers Test Fall 2023 Monovalent Shots
Eris, or EG5, is of Omicron lineage and accounts for ~17% of reported COVID-19 cases; mRNA vaccine producers are confident in the new shots to protect against it.
New Data Reveal How COVID-19 Vaccination Can Decrease Severity, Mortality Following SARS-CoV-2 Infection
Findings from a new study show the long-term benefits of COVID-19 vaccination to reduce inflammation after a breakthrough infection, say researchers.
Updated CDC Immunization Guidelines for 2023-2024 Tripledemic Viruses
CDC immunization recommendations for influenza, COVID-19, and RSV from the updated 2023 schedules are summarized in this Guideline Topline.
Daily Dose: Moderna, Pfizer COVID-19 Vaccines go Head-to-Head in Safety Study
A daily dose of clinical news on Patient Care you may have missed.
Flu Shots for Your Patients Aged ≥65 Years: 2 Questions
Which influenza vaccines does CDC recommend for older adults and how do the recommended shots differ from the others available? A short quiz.
Climate Change, Power Outages, and Vaccines—Oh No!
You have tens of thousands of dollars worth of vaccines in your office fridge; your area loses power for 5 days after flooding rain. Now what?
The Moderna mRNA COVID-19 Vaccine May Be Safer in Older Adults than the Pfizer Shot, New Study Suggests
The only head-to-head trial of mRNA COVID-19 vaccine safety in older adults finds one has a slight edge over the other, which might just be enough for some patients.
7 New Approved Drugs for Primary Care: Q2 2023
The end of another quarter means a new list of FDA-approved drugs for primary care. Which ones should you know about?
Merck's 21-Valent Adult Pneumococcal Vaccine Meets Key Endpoints in Pair of Phase 3 Trials
Statistically significant positive immune responses were observed in both vaccine-naive adults and those previously vaccinated, including for the vaccine's 8 unique serotypes.